search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


NT-proBNP Testing in Patients Presenting to the Emergency Department With Acute Dyspnea: Evaluation of Effects on Treatment, Hospitalisation Rate and Costs


- candidate number2550
- NTR NumberNTR956
- ISRCTNISRCTN28653133
- Date ISRCTN created30-mei-2007
- date ISRCTN requested22-mei-2007
- Date Registered NTR15-apr-2007
- Secondary IDs 
- Public TitleNT-proBNP Testing in Patients Presenting to the Emergency Department With Acute Dyspnea: Evaluation of Effects on Treatment, Hospitalisation Rate and Costs
- Scientific TitleNT-proBNP in Acute Dyspnea: Effects on Treatment, Hospitalisation and Costs
- ACRONYM
- hypothesisDiagnostic uncertainty in patients with complaints of shortness of breath presenting to the Emergency Department of a hospital may delay treatment and proper care. In patients with shortness of breath due to heart failure increased plasma levels of NT-pro-B-type natriuretic peptide (NT-proBNP) can be demonstrated. The use of NT-proBNP as a biomarker for heart failure in patients presenting to the emergency department with dyspnea might improve care and reduce length of hospital stay. In our study we will investigate the effect of introduction of NT-proBNP as biomarker for heart failure on treatment, time to discharge and costs.
- Healt Condition(s) or Problem(s) studiedB-type natriuretic peptide , Dyspnea , Costs, Cost-effectiveness
- Inclusion criteria1. Age 18 years or older; 2. Acute dyspnea as the most prominent complaint
- Exclusion criteria1. Acute dyspnea due to a trauma; 2. Acute dyspnea due to cardiogenic shock; 3. Renal failure requiring dialysis.
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingSingle
- controlNot applicable
- groupParallel
- Type-
- Studytypeintervention
- planned startdate 12-jan-2004
- planned closingdate5-jan-2008
- Target number of participants477
- InterventionsStudy-group: Measurement of NT-proBNP plasma level at presentation in the Emergency Department. Control-group: No measurement of NT-proBNP plasma level at presentation in the Emergency Department. Blood was collected for determination of NT-proBNP levels at the end of the study.
- Primary outcome1. Time to discharge; 2. Cost of treatment
- Secondary outcome1. Duration of stay at the ED; 2. Proportion of patients admitted to the hospital; 3. Proportion of patients admitted to an intensive or coronary care unit; 4. Specialist consultations; 5. Medical treatment; 6. Diagnostic investigations
- Timepoints
- Trial web site
- statusinclusion stopped: follow-up
- CONTACT FOR PUBLIC QUERIESMD J.H.W. Rutten
- CONTACT for SCIENTIFIC QUERIESMD, PhD A.H. Meiracker, van den
- Sponsor/Initiator Erasmus Medical Center, Department of Internal Medicine
- Funding
(Source(s) of Monetary or Material Support)
Mrace Comittee, Erasmus MC
- Publications
- Brief summaryElevated amino-terminal pro-B-type natriuretic peptide (NT-proBNP) plasma levels are indicative for heart failure. Assessment of this biomarker in patients with acute dyspnoea presenting to the emergency department may aid diagnostic decision-making; resulting in improved patient care and reduced costs. We will investigate the cost-effectiveness of introduction of NT-proBNP measurements in patients presenting with acute dyspnoea to the emergency department of the Erasmus MC, Rotterdam, the Netherlands. Subjects will be randomised for either rapid measurement of plasma NT-proBNP or no diagnostic measurement of NT-proBNP. For ruling out heart failure, cut-off values of 11 pmol/l in males and 17 pmol/l in female patients will be used, and for ruling in heart failure a cut-off value of 120 pmol/l. Time to discharge from the hospital and costs related to hospital admission are primary end-points.
- Main changes (audit trail)
- RECORD15-apr-2007 - 11-jun-2007


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl